Immutep (Immutep) Debt-to-Equity

: 0.01 (As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

Immutep's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.14 Mil. Immutep's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.94 Mil. Immutep's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $77.41 Mil. Immutep's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Immutep's Debt-to-Equity or its related term are showing as below:

IMMP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.16 Max: 0.31
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Immutep was 0.31. The lowest was 0.01. And the median was 0.16.

IMMP's Debt-to-Equity is ranked better than
99.91% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs IMMP: 0.01

Immutep Debt-to-Equity Historical Data

The historical data trend for Immutep's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.31

0.27

0.04

0.02

0.01

Immutep Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.01	N/A	0.01	N/A	0.01

Competitive Comparison

For the Biotechnology subindustry, Immutep's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Immutep's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Immutep's Debt-to-Equity falls into.

Immutep Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Immutep's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.124	+	0.7)	/	91.59
	=	0.01

Immutep's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.141	+	0.94)	/	77.405
	=	0.01

Immutep (NAS:IMMP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Immutep Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Immutep's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (Immutep) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PRRUF:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.